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ABSTRACT
Objective The aim of the present study was to evaluate the antifungal susceptibilities of 
isolates of Fusarium to amphotericin B, itraconazole and voriconazole.
Methods The susceptibility of 44 isolates of Fusarium was tested by the E-test metho-
dology. 
Results All the isolates were resistant to itraconazole, and 89 % and 54,5 % were resis-
tant to amphotericin B and voriconazole, respectively. 
Discussion The results confirm the high level of resistance reported, regardless of the 
species or the strain of Fusarium involved. The high MICs level observed are worrying 
and suggest that new drugs are needed.  
Key Words: Fusarium; amphotericin B; voriconazole (source: MeSH, NLM).
RESUMEN
Objetivo Evaluar la susceptibilidad antifúngica in vitro de aislamientos de Fusarium a 
los antimicóticos amfotericina B, itraconazol y voriconazol.
Métodos La susceptibilidad de 44 aislamientos clínicos de Fusarium fue evaluada por 
el método de difusión en disco, E-test.
Resultados Todos los aislamientos fueron resistentes al itraconazol, y 89 % y 54,5 % 
fueron resistentes a la amfotericina B y al voriconazol, respectivamente.
Discusión Los resultados confirman el alto nivel de resistencia reportado, indepen-
diente de la especie o la cepa de Fusarium involucrada. Los valores tan altos de MICs 
son preocupantes y sugieren la necesidad de evaluar nuevos medicamentos.
Palabras Clave: Fusarium; anfotericina B; voriconazol (fuente: DeCS, BIREME).
Fungi of the genus Fusarium are primarily plant pathogens and saprobes that cause a broad spectrum of infections in humans; including superficial, local, invasive, and disseminated infections, in immunologically deficient humans 
(1). After aspergillosis, disseminated fusariosis is the second most common cause 
of invasive infection by filamentous fungi in patients with hematologic malignan-
cies or those undergoing transplants of hematopoietic progenitors; its high mor-
tality rate and the lack of an optimal management protocol have raised increasing 
interest in this mycosis (2). 
The most frequent species causing fusariosis are F. solani, F. oxysporum, and F. 
verticillioides (1,3). Although less frequent, several other species also cause human 
infections. Some of these species are F. chlamydosporum, F. dimerum, F. incarna-
tum and also the following species that are included into the Gibberella fujikuroi 
species complex: F. napiforme, F. nygamai, F. proliferatum, and F. sacchari (4). 
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F. temperatum has been recently reported as an agent 
of keratitis (5). However, the relevance of one species 
could change depending on the geographic area and the 
kind of infection involved. In the North of Italy, F. ver-
ticillioides was the most frequent isolated species from 
deep-seated infections and, F. solani was the most fre-
quent isolated species from superficial infections (1). In 
Brazil, strains of F. solani have represented the 88 % of 
a total of 41 isolates involved in Fusarium keratitis (3), 
and in Bogotá (Colombia), F. solani, F. oxysporum and 
F. verticillioides represented the 64,9; 32,8; and 2,3 % 
respectively, from a total of 137 patient with onychomy-
cosis by Fusarium (6).
Fusarium is one of the most genetically heterogeneous 
fungi groups. Many species of this genus, that were iden-
tified —based on morphological characters— proved to 
be species complexes with little to no morphological di-
fferences, rather than single species (7). Many species, as 
F. solani, F. oxysporum, F. verticillioides, F. chlamydos-
porum and F. dimerum represent complexes of species (4). 
The huge genetic diversity of Fusarium, somehow is 
reflected in the susceptibility patrons to antifungals. Con-
troversial results of susceptibility to antifungal and a high 
level of resistance are reported. Some species are less 
sensible than others, or strains of the same species have 
different levels of susceptibility to the same product (1,7). 
The F. solani species complex is one of the group with the 
poorest response, in vitro and in vivo to different drugs, as 
well as one of the most heterogeneous genetically spea-
king (1,8,9). The F. fujikuroi species complex showed re-
sistance patterns species-specific (10). 
The triazoles represent the frontline drugs for the treat-
ment of mould diseases; nevertheless, emerging moulds 
(including Fusarium spp.,) may be less susceptible or 
resistant to these antifungals (11). Polyenes and azole 
compounds are routinely applied chemotherapy to fungal 
keratitis (12). Amphotericin B and voriconazole are the 
preferred drugs of choice for treatment of deep and disse-
minated infections, although some Fusarium species are 
not susceptible to them (7). However; good results have 
also been found, with better activity of the amphotericin B 
than the voriconazole (1,3,13) or voriconazole with better 
activity than amphotericin B (1,14).
Therefore, taking into account that the data of anti-
fungal susceptibility of Fusarium spp are conflicting and 
could depend on the species, strain, kind of fusariosis and 
the antifungal drug (13), we have studied the susceptibi-
lity of 44 clinical isolates of Fusarium to amphotericin b, 
itraconazole and voriconazole by the E-test methodology. 
The results showed that all the Fusarium isolates were 
resistance to the itraconazole and 89 % of them to ampho-
tericin B, too. Voriconazole had a moderate activity; only 
15, 9 % of the isolates were sensible. These suggest that 
others antifungals should be considered.
METHODOLOGY
Isolates 
The isolates were recovered from patients at the Corpo-
ración para Investigaciones Biológicas (CIB) in Medellin 
(Colombia) since 2004 to 2006. A total of 44 Fusarium 
isolates, from toenails (n=35), hand nails (n=2), skin 
(n=4) and cornea (n=1) were evaluated. These were iden-
tified as Fusarium spp, by the direct exam in Chinese ink 
and KOH at 20 %, and by their macroscopic and micros-
copic morphological features after they were cultured 
in the media Sabouraud, potato dextrose agar (PDA) and 
Mycosel at 23 ºC for one to three weeks. The identity to 
the specie level of 35 isolates was determined by partial 
sequence of the transduction elongation factor gene (TE-
F1a), in another work (15). All the isolates were preserved 
in sterile water at room temperature in darkness. 
Antifungal susceptibility
The in vitro activity of amphotericin b, itraconazole and 
voriconazole was evaluated against 44  isolates of Fusa-
rium, by the disk diffusion test according to the methods 
provided in CLSI M38-A (16,17). 
The isolates were sub-cultured on PDA plates and in-
cubated at 25 ºC for seven days. Each colony was reco-
vered with 10 ml of distilled water into a glass sterile 
tube; and after sedimented for 20 min., the upper part of 
each tube was collected in a new sterile tube. The sus-
pensions were adjusted to a transmittance of 68–70 % at 
530 nm, with distilled water, corresponding to an inocu-
lum of 106 UFC/ml. A volume of 200 μl of each inocu-
lum was added onto plates with 16 ml of RPMI medium 
supplemented with 1,5 % of agar, 2 % of glucose, at pH 
7, and 0,165 M of buffer MOPS (Morpholine propane sul-
fonic acid, AES laboratory, Paris, France). The inoculum 
was allowed to dry for 15–30 minutes. 
The E-test method was performed by following the ins-
tructions of the manufacturer (Etest®-AB Biomérieux). The 
antifungal agents were tested in concentrations than ranged 
from 256 to 0,016 µg/ml; two strips with the antifungal con-
centration, were placed in opposite direction on the inocu-
lum. These were cultured at 28 ºC. The MICs that produced 
inhibition of growth were read after 48 hours, by visual exa-
mination; MICs were recorded as the lowest drug concentra-
tion where the border of the inhibition ellipse intersects with 
the scale on the plastic antifungal strip. Candida krusei ATCC 
6 258 was included as a quality control strain (18).
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RESULTS
The results showed that all the 44 isolates of Fusarium 
evaluated, except the control (C. krusei) were resistant to 
itraconazole; 39 of the isolates (representing the 89 %) 
were also resistant to amphotericin B; the others five were 
intermediate or sensible dose-dependent (two of F. oxys-
porum and two of F. solani, and the other isolate —63 
946— was not identified)  (Table 1). 
The voriconazole was the only antifungal that showed 
moderate activity, with seven isolates (representing the 
15,9 %) sensible to the product (with MICs of less than 1 
µg/ml); five of them were identified as F. oxysporum (the 
two remaining were not identified); 13 isolates (29,6 %) 
were sensible dose-dependent; six of F. oxysporum; three 
of F. solani and one of F. incarnatum (56 665); the three 
remaining were not identified. The others 24 isolates (re-
presenting the 54,5 %) were resistant to voriconazole; 10 of 
F. oxysporum; 10 of F. solani, and 4 that were no identified. 
All the isolates resistant to voriconazole were also resis-
tant to amphotericin B and itraconazole. All of them were 
taken from nails, except for the isolate 56 988 of F. solani, 
which was taken from the cornea (Table 1). It is important 
to highlight the number of isolates with MICs higher than 
32 µg/m: 44 (all the isolates), 36 and four to itraconazole, 
amphotericin B and voriconazole, respectively.
Table 1. Antifungal susceptibilities of clinical isolates of Fusarium to amphotericin B, 
 itraconazole and voriconazole by the E-test method
Strain Origen Gender Voriconazole Itraconazole Amphotericin B
Control 24 hours - 0,125 0,125 0,047
Control 48 hours - 0,25 0,75 1
55349 Toenails F 1,5 >32 >32
55444 Toenails M 2 >32 2
55496 Toenails F 0,75 >32 >32
55529 Toenails M 4 >32 >32
55583 unknown M 1,5 >32 >32
55787 Toenails F 1,5 >32 >32
55861 Toenails F 2 >32 >32
55945 Toenails F 1 >32 >32
56054 Skin M 2 >32 3
56212 Toenails F 1,5 >32 >32
56240 Toenails F 6 >32 16
56242 Toenails M 4 >32 >32
56301 Toenails F 8 >32 >32
56363 Toenails F 0,75 >32 >32
56665 Skin F 1 >32 >32
56780 Toenails F 4 >32 >32
56891 Toenails M 2 >32 0,19
56894 Toenails M 4 >32 4
56988 Cornea M 8 >32 16
57221 Toenails F 1,5 >32 >32
57560 Toenails F 1 >32 >32
57855 Toenails F >32 >32 >32
57949 Toenails F 1 >32 >32
57952 Toenails F 0,5 >32 >32
63051 Skin M 1,5 >32 >32
63447 Toenails F 1 >32 >32
63550 Toenails F >32 >32 >32
63635 Toenails F 2 >32 >32
63648 Toenails F 0,5 >32 >32
63649 Toenails F 8 >32 >32
63666 Hand nails F 3 >32 >32
63746 Toenails M 0,5 >32 >32
63749 Hand nails M 8 >32 >32
63768 Toenails F 2 >32 >32
63783 Toenails F >32 >32 >32
63786 Toenails F >32 >32 >32
63857 Skin F 0,75 >32 >32
63868 Toenails F 2 >32 >32
63880 Toenails F 0,25 >32 3
63901 Toenails F 6 >32 >32
63917 Toenails F 8 >32 >32
63946 Toenails F 1,5 >32 2
64938 Toenails M 1,5 >32 >32
64945 - - 16 >32 >32
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DISCUSSION
Fusarium spp., is a well-known opportunistic fungal 
agent that can cause important infections in immuno-
compromised patients. It is also one of the main myco-
toxigenic fungi (19). Fusarium is the leading pathogen 
of fungal keratitis in most of the studies worldwide, 
particularly in tropical regions (3); its ability to form 
biofilm was suggested as a contributing factor in recent 
outbreaks (9). Fusarium spp. have frequently been iso-
lated from patients with onychomycosis, mainly of the 
specie F. oxysporum (6).
The typical profile of the antifungal susceptibility of 
Fusarium spp. is the resistance to most antifungal agents. 
Due to the susceptibility pattern of Fusarium spp., the 
antifungal therapy options are limited (20). Additionally, 
information on epidemiology, antifungal susceptibilities 
and correlation with clinical outcomes is lacking, and 
such information is useful from a prognostic, diagnostic 
and therapeutic viewpoint (3). On the other hand, MICs 
break points are not available for mold testing, therefo-
re the isolates has been grouped as susceptible (MIC or 
MEC,<1µg/ml), intermediate (MIC or MEC, 2 µg/ml) and 
resistant (MIC or MEC, >4 µg/ml), based on reported in 
vitro data obtained with large numbers of isolates (17,21). 
The levels for the antifungal that we evaluated were: <1, 
1-2, >2 µg/ml for sensible, sensible dose-dependent and 
resistant, respectively.  
In our work, the epidemiological data showed that, 
from the 44 clinical isolates, 84 % were involved in on-
ychomycosis and 70 % were taken from females, which 
suggest that the generalized practice of manicure and pe-
dicure in Colombia could be contributing to the disper-
sion of Fusarium spp. The most prevalent specie was F. 
oxysporum, with 60 % (21 of 35 isolates previously iden-
tified), followed by F. solani with 37 % and F. incarnatum 
with one isolate, in agreement with previous reports (6).
The data of susceptibility of Fusarium spp., to antifun-
gal drugs are conflicting (13); different works have shown 
that the susceptibility is species-related, with F. solani ha-
ving the highest MICs values (1,8,9), or strain-related as 
those biofilm producers, over all of F. solani (3). The sus-
ceptibility to the same antifungal is variable. It seems that 
itraconazole has a poor activity against Fusarium spp., 
as we found in our work. In some cases, amphotericin B 
has shown better activity than voriconazole (1,3,13), or in 
some others, voriconazole is better than amphotericin B 
(14), in agreement with our work. 
A better efficacy of the amphotericin B than itraconazole 
against strains of different clades of F. solani has been re-
ported (8). Similarly, the amphotericin B has been shown as 
the most active drug against F. solani, while voriconazole 
and posaconazole were active against other Fusarium spe-
cies (1). Strains of F. solani that produce biofilms has lower 
susceptibility, mainly for amphotericin B, which seems to 
be related with a worse clinical outcomes for F. solani com-
pared with other Fusarium species (3).
In a study made in the United States of America it was 
found that, from the isolates involved in keratitis, the spe-
cies of F. solani were the most common, followed by F. 
oxysporum species; and more strains of F. solani formed 
biofilm than strains of F. oxysporum, and the ability to form 
biofilm varied by strain and clade type (9). None of the iso-
lates of F. solani of our work was sensitive to voriconazole; 
instead, there was of F. oxysporum, although the isolates 
came from patient with onychomycosis mainly. 
Voriconazole has been used to treat fungal infections 
in immunocompromised patients, including those caused 
by Fusarium spp (6). In our work, voriconazole was the 
best of the three antifungals evaluated against Fusarium 
spp., although only the 15, 9 % and 29 %, 6 % of the 
isolates was sensible and sensible dose-dependent, res-
pectively to the product. As we have said, all the sen-
sitive isolates belong to F. oxysporum and, from the 13 
isolates (29,6 %) sensibles dose-dependent, six were of 
F. oxysporum, three of F. solani and one of F. incarnatum 
(the remaining three were not identified), which suggest 
that F. solani strains are less sensible. However, equal 
number of strains (ten) of F. oxysporum and F. solani 
were found resistant to voriconazole. Similarly, in ano-
ther study made in Colombia with 137 patients with on-
ychomycosis by Fusarium spp., the highest MICs values 
with voriconazole were of the isolates of F. solani, fo-
llowed by F. oxysporum and F. verticillioides; 83.9 % and 
66.7 % of the F. solani and F. oxysporum isolates were 
resistant to voriconazole, respectively (6). 
Fusarium spp. show higher MICs value compared to 
other genus (6). In a study made in Colombia, the in vi-
tro activity of fluconazole, itraconazole, voriconazole 
and terbinafine against fungi causing onychomycosis by 
species of Candida,  Fusarium, Fusicoccum dimidiatum, 
Scytalidium hyalinum and dermatophytes showed that 
the Fusarium species had the highest MIC values, with all 
the antifungal agents, compared to the other fungal ge-
nera (22). In agreement with our work, they found the 
highest MICs values with itraconazole to F. solani and F. 
oxysporum, while voriconazole showed lower values but, 
contrary to our results, the isolates of F. oxysporum were 
less sensible than those of F. solani (between 2-16 and 
2-8 µg/mL, respectively) (22). Also, they reported more 
species of Fusarium: six isolates of F. oxysporum, two of 
F. solani, one of F. proliferatum, one F. dimidiatum, and 
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one of F. nygamai (22); however, the differences between 
the methods for identification of isolates between these 
two works should be considered.
A few works have compared numerous antifungal pro-
ducts against Fusarium spp. The antifungal susceptibili-
ties from a strain collection of 48 isolates of Fusarium, 
belonging to the less-common Fusarium species of cli-
nical interest, F. chlamydosporum, F. dimerum, F. incar-
natum, F. napiforme, F. nygamai, F. proliferatum, and F. 
sacchari was evaluated against 11 antifungal drugs (in-
cluding amphotericin b, itraconazole and voriconazole) 
(13). Terbinafine was the most active drug against all the 
species tested with the exception of F. incarnatum, for 
which amphotericin B was the most active; amphotericin 
b was the second most active drug and, voriconazole al-
though showed poor activity against all the tested strains. 
It was the third most active antifungal drug (13). 
In Brazil, the in vitro susceptibility of isolates of F. 
napiforme responsible for a disseminated fusariosis were 
evaluated against amphotericin B, itraconazole, voricona-
zole, micafungin, 5-flucytosine, miconazole and flucona-
zole. The isolates were resistant to amphotericin B, with 
MIC ranging from 2 to 4 µg/mL; the azoles were the most 
active against all the tested isolates (14).
In summary, the in vitro and in vivo activity against 
Fusarium species is not predictable. The unsatisfactory 
susceptibility profiles in vitro can be attributed to seve-
ral factors, including the species of Fusarium, the strain, 
and the kind of antifungal drug. In vivo other factors are 
affecting too, as the kind of fusariosis and the underlying 
disease of the patient. Therefore, the choice of the anti-
fungal should be determined on a case-by-case basis, de-
pending on the species and susceptibilities performed at 
an experienced center, whenever feasible to obtain (22).
As it has been said “…despite of the methodological ad-
vance for determining antifungal susceptibility for fungi, the in-
terpretation of the results and determination of how best to use 
these results continue to cause considerable confusion” (21), 
seems to be the best interpretation of the susceptibili-
ty of Fusarium. Therefore, categorical conclusions are 
impossible, but for our local area in Colombia, itraco-
nazole should not be used for the treatment of fusario-
sis; nor amphotericin b, since any of the isolates was 
sensible to it. Voriconazole could be used but a test is 
always required 
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